Abstract
We thank Drs Zhang and Yang for their comments. In their letter, Drs Zhang and Yang raised the possibility that the cardiotoxicity seen in our cohort may have been predominantly due to the effect of anthracyclines rather than trastuzumab. They cited three studies; a meta-analysis of 6 randomized control trials by Antonis Valachis et al. which showed a low rate of severe cardiac toxicity in patients treated with trastuzumab alone 1 ; a study by de Azambuja et al. which demonstrated that the cardiotoxicity induced by trastuzumab was reversible 2 ; and a study by Adamo et al. which reported that trastuzumab-based treatments were well-tolerated in a small cohort of 51 elderly patients > 70 years old with adverse events that were deemed only mild to moderate in severity 3 ; to support their argument that trastuzumab caused very limited cardiotoxicity.
| Original language | English |
|---|---|
| Pages (from-to) | 1129-1130 |
| Number of pages | 2 |
| Journal | Journal of the American Society of Echocardiography |
| Volume | 28 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - Sept 2015 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Author's Reply: does trastuzumab cause cardiotoxicity in the treatment of patients with breast cancer?'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver